ATE454396T1 - Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure - Google Patents

Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure

Info

Publication number
ATE454396T1
ATE454396T1 AT05791236T AT05791236T ATE454396T1 AT E454396 T1 ATE454396 T1 AT E454396T1 AT 05791236 T AT05791236 T AT 05791236T AT 05791236 T AT05791236 T AT 05791236T AT E454396 T1 ATE454396 T1 AT E454396T1
Authority
AT
Austria
Prior art keywords
hydrocromic
purified
acid
producing polypeptide
polypeptide mixtures
Prior art date
Application number
AT05791236T
Other languages
English (en)
Inventor
Ben-Zion Dolitzky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36037047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE454396(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE454396T1 publication Critical patent/ATE454396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05791236T 2004-09-09 2005-09-09 Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure ATE454396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60884304P 2004-09-09 2004-09-09
PCT/US2005/032395 WO2006029393A2 (en) 2004-09-09 2005-09-09 Process for preparation of mixtures of polypeptides using purified hydrobromic acid

Publications (1)

Publication Number Publication Date
ATE454396T1 true ATE454396T1 (de) 2010-01-15

Family

ID=36037047

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10150124T ATE536363T1 (de) 2004-09-09 2005-09-09 Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure
AT05791236T ATE454396T1 (de) 2004-09-09 2005-09-09 Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT10150124T ATE536363T1 (de) 2004-09-09 2005-09-09 Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure

Country Status (27)

Country Link
US (2) US7495072B2 (de)
EP (3) EP2177528B1 (de)
JP (1) JP5149008B2 (de)
KR (1) KR101317131B1 (de)
CN (1) CN101166754B (de)
AT (2) ATE536363T1 (de)
AU (1) AU2005282249B2 (de)
BR (1) BRPI0515033B1 (de)
CA (1) CA2579656C (de)
CY (1) CY1110280T1 (de)
DE (1) DE602005018800D1 (de)
DK (3) DK2177528T3 (de)
ES (3) ES2338138T3 (de)
HR (3) HRP20100164T1 (de)
IL (2) IL181596A (de)
IS (1) IS8622A (de)
MX (1) MX2007002760A (de)
NO (1) NO20071632L (de)
NZ (1) NZ554018A (de)
PL (3) PL2361924T3 (de)
PT (3) PT2177528E (de)
RS (3) RS51257B (de)
RU (1) RU2388764C2 (de)
SI (3) SI2361924T1 (de)
UA (1) UA91029C2 (de)
WO (1) WO2006029393A2 (de)
ZA (1) ZA200702591B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
KR100657048B1 (ko) * 2001-12-04 2006-12-12 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트의 효능 측정 방법
AU2005218625A1 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
BRPI0515033B1 (pt) * 2004-09-09 2021-05-25 Teva Pharmaceutical Industries, Ltd Processo para a obtenção de uma mistura de polipeptídeos de trifluoroacetila, mistura de polipeptídeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica e para a produção de acetato de glatirâmero
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
ATE440888T1 (de) * 2004-10-29 2009-09-15 Sandoz Ag Verfahren zur herstellung von glatiramer
EP1838326A4 (de) * 2005-02-02 2009-09-30 Teva Pharma Verfahren zur herstellung von polypeptidmischungen mittels hydrogenolyse
WO2006089164A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006116602A2 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
US20090035816A1 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
BRPI0819001A2 (pt) * 2007-11-28 2014-10-07 Teva Pharma "método para retardar o acesso de esclerose múltipla clinicamente defenitiva em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão da atividade de doença monitorada por imagem latente de ressonância magnética (mri) em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão dos sintomas de esclerose múltipla definitiva em um paciente, método para reduzir a freqüência de recidiva em um paciente que experimentou um ataque clínico simples sugestivo de esclerose múltipla e que tem pelo menos uma lesão sugestiva de esclerose múltipla, método para retardar a progressão para a esclerose múltipla clinicamente definitiva em um paciente que apresenta um primeiro evento clínico sugestivo de esclerose múltipla e pelo menos uma lesão sugestiva de esclerose múltipla, uso de acetato de glatiramer e acetato de glatiramer
EP2277050B2 (de) 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analyse von aminosäurecopolymerzusammensetzungen
HUE025042T2 (en) * 2008-08-07 2016-07-28 Sigma Aldrich Co Llc High-yield production of low molecular weight polylysine and poliornitine
AU2009279636A1 (en) * 2008-08-07 2010-02-11 Scinopharm Taiwan, Ltd. Synthesis of glatiramer acetate
EP2414384B2 (de) 2009-04-03 2023-05-03 Momenta Pharmaceuticals, Inc. Steuerung von copolymerzusammensetzungen
HUE031282T2 (hu) 2009-08-20 2017-06-28 Yeda Res & Dev Alacsony gyakoriságú glatiramer acetát terápia
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ603012A (en) * 2010-04-27 2015-01-30 Reddy’S Lab Ltd Dr Preparation of polypeptides and salts thereof
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
US8788046B2 (en) 2010-11-11 2014-07-22 Spr Therapeutics, Llc Systems and methods for the treatment of pain through neural fiber stimulation
ES2654291T3 (es) 2011-02-14 2018-02-13 Usv Private Limited Copolímero-1, proceso para la preparación y sus métodos de análisis
JP5701103B2 (ja) * 2011-03-02 2015-04-15 昭和シェル石油株式会社 潤滑油のための消泡剤組成物及びそれを用いた消泡方法
EP2699317B1 (de) 2011-04-21 2016-08-10 Mapi Pharma Limited Zufallspentapolymer zur behandlung von autoimmunkrankheiten
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CN102717992A (zh) * 2012-05-30 2012-10-10 苏州市旭洋工业搪瓷厂 一种搪玻璃溴素贮罐
CN102718963B (zh) * 2012-06-19 2014-10-15 深圳翰宇药业股份有限公司 聚合物多肽的制备方法
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015066515A1 (en) 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CN104844697B (zh) * 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CA3035147A1 (en) 2016-08-31 2018-03-08 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
JP7602322B2 (ja) 2017-03-26 2024-12-18 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
US20190202984A1 (en) * 2018-01-03 2019-07-04 Kinbio Ltd. Process of preparing glatiramer acetate

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846550A (en) 1971-01-21 1974-11-05 H Akrongold Cosmetic skin powder containing urea
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS54119499A (en) * 1978-03-09 1979-09-17 Shionogi & Co Ltd Triazolobenzodiazepin derivative
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
DE3681144D1 (de) 1985-06-18 1991-10-02 Univ Emory Verwendung biologisch aktiver copolymere zur herstellung eines arzneimittels zur stimulierung des wachstums von tieren.
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
USH1312H (en) * 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
RU2198900C2 (ru) * 1994-05-24 2003-02-20 Еда Рисерч энд Дивелопмент Ко., Лтд. Усовершенствованный сополимер-1 и способ его получения
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
FR2750423B1 (fr) 1996-06-28 1998-08-14 Rhone Poulenc Chimie Procede d'hydrogenation asymetrique d'un compose cetonique
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6525042B1 (en) 1997-09-30 2003-02-25 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
US5872122A (en) * 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
US5965047A (en) 1997-10-24 1999-10-12 Steag Ast Rapid thermal processing (RTP) system with rotating substrate
GB9724627D0 (en) 1997-11-20 1998-01-21 Genencor Int Bv Gram positive microorganism formate pathway
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
CA2355400A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co., Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
US6114649A (en) 1999-07-13 2000-09-05 Duran Technologies Inc. Anode electrode for plasmatron structure
WO2001018248A2 (en) 1999-09-03 2001-03-15 The University Of Iowa Research Foundation Quorum sensing signaling in bacteria
DE19944003C1 (de) 1999-09-14 2001-03-22 Baumeister & Ostler Gmbh Co Faltbare Trenneinrichtung
CN100360180C (zh) * 2000-01-20 2008-01-09 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
EP1261361B1 (de) 2000-02-18 2006-06-14 Yeda Research And Development Company, Ltd. Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001093893A2 (en) 2000-06-07 2001-12-13 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
JP3698984B2 (ja) 2000-11-10 2005-09-21 ヤマウチ株式会社 シュープレス用ベルト
JP2004517074A (ja) * 2000-11-20 2004-06-10 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環アリールおよびヘテロアリールピリジン類
JP3661935B2 (ja) 2001-06-20 2005-06-22 ソニー株式会社 情報処理装置および方法、記録媒体、並びにプログラム
KR100657048B1 (ko) * 2001-12-04 2006-12-12 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트의 효능 측정 방법
AU2003301457A1 (en) 2002-05-09 2004-05-04 Keith Baumann Bioweapon-detecting fibrous-network products and methods for making same
EP1565486A2 (de) 2002-11-13 2005-08-24 Apotex Pharmachem Inc. Verfahren zur herstellung von glatirameracetat durch polymerisierung von n-carbonsäureanhydriden vonl-alanin, l-tyrosin, benzyl-l-glutamat und benzyloxycarbonyl-l-lysin
CA2411786C (en) * 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
DE10353960B4 (de) 2003-10-16 2006-03-23 Vertilas Gmbh Oberflächenemittierender Halbleiterlaser mit strukturiertem Wellenleiter
BRPI0515033B1 (pt) 2004-09-09 2021-05-25 Teva Pharmaceutical Industries, Ltd Processo para a obtenção de uma mistura de polipeptídeos de trifluoroacetila, mistura de polipeptídeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica e para a produção de acetato de glatirâmero
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
EP1838326A4 (de) 2005-02-02 2009-09-30 Teva Pharma Verfahren zur herstellung von polypeptidmischungen mittels hydrogenolyse
WO2006116602A2 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007072865A1 (ja) 2005-12-22 2007-06-28 Pioneer Corporation 施設情報配信装置、通信端末、施設情報配信方法、情報出力方法、プログラム、および記録媒体

Also Published As

Publication number Publication date
HRP20140216T1 (hr) 2014-06-06
DK1799703T3 (da) 2010-04-19
US20070021324A1 (en) 2007-01-25
CN101166754A (zh) 2008-04-23
HK1156637A1 (en) 2012-06-15
ES2451006T3 (es) 2014-03-26
IS8622A (is) 2007-03-16
RU2007112956A (ru) 2008-10-20
ATE536363T1 (de) 2011-12-15
HK1100780A1 (en) 2007-09-28
DK2361924T3 (en) 2014-03-10
MX2007002760A (es) 2007-05-18
EP2177528B1 (de) 2011-12-07
CY1110280T1 (el) 2015-01-14
HK1140775A1 (en) 2010-10-22
SI2177528T1 (sl) 2012-04-30
CN101166754B (zh) 2014-04-23
HRP20100164T1 (hr) 2010-07-31
WO2006029393A3 (en) 2007-12-13
BRPI0515033A8 (pt) 2019-01-22
JP2008512494A (ja) 2008-04-24
AU2005282249B2 (en) 2012-08-02
EP2361924B1 (de) 2013-12-11
PT1799703E (pt) 2010-03-04
PL2361924T3 (pl) 2014-08-29
JP5149008B2 (ja) 2013-02-20
CA2579656A1 (en) 2006-03-16
US7495072B2 (en) 2009-02-24
US20060052586A1 (en) 2006-03-09
BRPI0515033A (pt) 2008-07-01
WO2006029393A2 (en) 2006-03-16
EP1799703A2 (de) 2007-06-27
RS52265B (sr) 2012-10-31
SI2361924T1 (sl) 2014-04-30
BRPI0515033B1 (pt) 2021-05-25
EP2177528A1 (de) 2010-04-21
SI1799703T1 (sl) 2010-04-30
EP1799703A4 (de) 2008-09-03
KR101317131B1 (ko) 2013-10-10
ES2382298T3 (es) 2012-06-07
EP1799703B1 (de) 2010-01-06
HRP20120209T1 (hr) 2012-06-30
NZ554018A (en) 2009-06-26
CA2579656C (en) 2014-11-04
RS51257B (sr) 2010-12-31
WO2006029393A8 (en) 2007-04-19
DE602005018800D1 (de) 2010-02-25
AU2005282249A1 (en) 2006-03-16
EP2361924A1 (de) 2011-08-31
PT2361924E (pt) 2014-03-13
UA91029C2 (uk) 2010-06-25
ZA200702591B (en) 2009-03-25
RS53248B (sr) 2014-08-29
KR20070059137A (ko) 2007-06-11
PL1799703T3 (pl) 2010-06-30
PL2177528T3 (pl) 2012-09-28
PT2177528E (pt) 2012-03-19
IL181596A (en) 2015-10-29
DK2177528T3 (da) 2012-03-26
IL241702A0 (en) 2015-11-30
RU2388764C2 (ru) 2010-05-10
ES2338138T3 (es) 2010-05-04
IL181596A0 (en) 2007-07-04
NO20071632L (no) 2007-06-05

Similar Documents

Publication Publication Date Title
ATE454396T1 (de) Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
DE60320362D1 (de) Verfahren zur Herstellung von Dipeptiden
DE60230274D1 (de) Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämmen mit verstärkter expression des pts-g
UA93669C2 (ru) Способ приготовления полипептидной смеси c использованием гидрогенолиза
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
ATE334998T1 (de) Verfahren zur herstellung cyclischer peptide
ATE341640T1 (de) Verfahren zur herstellung von nicht-proteinogenen l-aminosäuren
ATE154609T1 (de) Nicht-lineare peptide, die hydropatisch komplementär zu bekannten aminosäuresequenzen sind, verfahren zur herstellung und verwendung davon
ATE411281T1 (de) Verfahren zur herstellung von s-aryl-cystein
DE602004028239D1 (de) Protease, für die protease codierende dna und verfahren zur herstellung der protease
DE50313042D1 (de) Nukleotidsequenzen codierend für deregulierte phosphoglycerat-dehydrogenasen coryneformer bakterien sowie verfahren zur herstellung von l-serin
EP1467207A4 (de) Screening-verfahren
DE602005016857D1 (de) Verfahren zur Herstellung von Tripeptid-Zwischenprodukten zur Herstellung von LHRH-Antagonisten
CY1115096T1 (el) Διαδικασια για την παρασκευη μιγματων trifluoroacetyl glatiramer acetate χρησιμοποιωντας καθαρισμενο υδροβρωμικο οξυ
ATE529437T1 (de) Verfahren zur sauerstoff-regulierten produktion von recombinanter staphylokinase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1799703

Country of ref document: EP